Tysabri Return To Market With Expanded Indication Backed By Committee
By
The Pink Sheet / Email the Author / “The Pink Sheet” Mar. 13, 2006, Vol. 68, No. 011
Advisory Committees / Word Count: 1337 / Article # 00680110001
Executive Summary
Biogen Idec's Tysabri could return to market as early as April with an expanded indication following review by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 7-8
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.